Back to Results

Filana Therapeutics, Inc (FLNA)

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program is simufilam, a small-molecule drug candidate being evaluated in Phase 3 clinical trials for Alzheimer’s disease. The company also advances SavaDx, an investigational diagnostic program designed to detect Alzheimer’s disease from a small blood sample and remains at an early stage of development. Formerly known as Cassava Sciences, Inc., the company adopted its current name in March 2026. Filana Therapeutics was incorporated in 1998 and is headquartered in Austin, Texas.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-FLNA
$0.98
33.7% Upside
Undervalued
$6.50
790.4% Upside
Bargain
Fair
0.0%
November 11, 2026
0.5x
35.072 M
-47.708 M
0.0%
97.9%
-9.4
69.3%
Valuation • Fair Value

Filana Therapeutics, Inc (NASDAQ-FLNA) Fair Value by Valuation Model

Review the available estimates for Filana Therapeutics, Inc (NASDAQ-FLNA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.98

Estimated upside of 33.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.98

Comparable-company valuation reference.

Analyst Price Target

$6.50

Analysts imply upside of 790.4%.

How to read these valuation models

Use the 4 available valuation references for Filana Therapeutics, Inc (NASDAQ-FLNA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Filana Therapeutics, Inc (NASDAQ-FLNA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-12.688 M

Current operating profitability reference.

EBITDA Forecast

67.2 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Filana Therapeutics, Inc (NASDAQ-FLNA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Filana Therapeutics, Inc (NASDAQ-FLNA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-9.4

Lower score that deserves closer risk review.

FCF / Net Income

69.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Filana Therapeutics, Inc (NASDAQ-FLNA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Filana Therapeutics, Inc (NASDAQ-FLNA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Filana Therapeutics, Inc (NASDAQ-FLNA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Filana Therapeutics, Inc (NASDAQ-FLNA) Stock Forecast & Technical Outlook

Review Filana Therapeutics, Inc (NASDAQ-FLNA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Filana Therapeutics, Inc (NASDAQ-FLNA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Filana Therapeutics, Inc (NASDAQ-FLNA) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Filana Therapeutics, Inc (NASDAQ-FLNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Filana Therapeutics, Inc (NASDAQ-FLNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Filana Therapeutics, Inc (NASDAQ-FLNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Filana Therapeutics, Inc (NASDAQ-FLNA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Filana Therapeutics, Inc (NASDAQ-FLNA) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Filana Therapeutics, Inc (NASDAQ-FLNA) Stock FAQ

Data-supported answers about Filana Therapeutics, Inc (NASDAQ-FLNA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.98
Estimated upside 33.7%
Valuation Rating
Undervalued
Estimated upside of 33.7%
Analyst Target
$6.50
Implied upside 790.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Filana Therapeutics, Inc (NASDAQ-FLNA) is $0.98. This implies an estimated upside of 33.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 33.7% versus the current market price.

The available analyst price target for Filana Therapeutics, Inc (NASDAQ-FLNA) is $6.50. The analyst target implies estimated upside of 790.4%.

The current financial health read for Filana Therapeutics, Inc (NASDAQ-FLNA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Filana Therapeutics, Inc (NASDAQ-FLNA) is November 11, 2026.

The latest available data indicates no current dividend yield for Filana Therapeutics, Inc (NASDAQ-FLNA).

The current market capitalization listed for Filana Therapeutics, Inc is 35.072 M.

The current enterprise value listed for Filana Therapeutics, Inc is -47.708 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Filana Therapeutics, Inc is NASDAQ-FLNA, and the stock is listed on NASDAQ.

Filana Therapeutics, Inc (NASDAQ-FLNA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Filana Therapeutics, Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Filana Therapeutics, Inc is 97.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B